Spine, a Division of Stryker Corporation, from August 2004 through December 2007. Prior to that, Mr. Errico co-founded and served as the Chief
Executive Officer and director for Spinecore, Inc., from September 2001 through August 2004, when that company was sold to Stryker Corporation. Mr. Errico received his B.S. in Aeronautical Engineering from the Massachusetts Institute of
Technology, his M.S. in Mechanical Engineering and Materials Science from Duke University School of Engineering and his J.D. from Duke University School of Law. Mr. Errico also serves as the Managing Member of Core Ventures II, LLC and certain
affiliated entities with an equity interest in the Company. The Board believes that Mr. Erricos extensive senior management experience in innovative healthcare technology companies, and his extensive knowledge and contributions to the
Companys intellectual property, products, business, and the science of VNS, qualifies him to serve on the Board.
Trevor J. Moody
Trevor J. Moody, 55, has served as a member of the Board since March 2013. Mr. Moody has served since January 2010 as President of TM Strategic Advisors
LLC, a management consultancy serving the boards, investors, and senior management of both emerging and
established medical technology companies. He also
currently serves as Medical Device Partner at MH Carnegie & Co. Pty Ltd (since October 2013), where he makes venture capital investments in medical device companies. From July 2015 to December 2015, Mr. Moody served as interim CEO of a
MH Carnegie & Co. portfolio company, Cardiac Dimensions Pty Ltd. From 1999 to 2010, Mr. Moody was at Frazier Healthcare Ventures, a large healthcare-focused venture capital and private equity investment firm. He was a General Partner
at Frazier Healthcare Ventures from 2005 to 2010. Prior to that, he was a Senior Consultant at The Wilkerson Group, a leading healthcare strategic consultancy. Mr. Moody currently also serves on the board of directors of a non-profit called Angel Flight West, and on the boards of several private corporations, including EBR Systems, Inc., Renew Medical Pty Ltd, Serene Medical Pty Ltd, Brain Protection Company Pty Ltd, CurvaFix, Inc.,
and Simplify Medical Pty Ltd. Mr. Moody received his Bachelor of Engineering from the University of Southern Queensland, Australia, and his M.S. in Management from the Massachusetts Institute of Technology (Sloan School). The Board believes
that Mr. Moodys experience, with over 25 years in the development, commercialization and funding of innovative, growth-oriented medical technologies, qualify him to serve on the Board.
Thomas M. Patton
Thomas M. Patton, 56, has
served as a member of the Board since April 2, 2020. He is a seasoned healthcare executive and board member with operational, strategic, financial, legal, compliance and transactional experience, from
start-ups to growth companies, both public and private. He last served as President and Chief Executive Officer of CAS Medical Systems, a publicly traded developer and distributor of patient monitoring
equipment, from 2010-2019. His prior experience includes as Co-Founder, President and CEO of QDX, Inc., a developer of unique micro-fluidic diagnostic technology utilizing digital imaging techniques for
hematologic analysis, as President and Chief Operating Officer of Novametrix Medical Systems, Inc., and CEO of Wright Medical Technology, Inc. Mr. Patton has served on 11 separate boards of directors for both public and private medical products
and services companies, and currently serves on the Board of Misonix, Inc., a publicly traded ultrasonic surgical tools and wound care company. The Board believes that Mr. Pattons business and financial experience, as well as his medical
device industry expertise, qualify him to serve on the Board.
Required Vote
Regarding Proposal 2, the election of directors, the Boards nominees will be elected by a plurality of the votes of the shares present in person or
represented by proxy and entitled to vote on the election of directors, and which did not abstain. Only votes For, For all, or Against will affect the outcome with respect to this proposal, and abstentions will
have no effect.
THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS
A VOTE FOR ALL WITH RESPECT TO PROPOSAL NO. 2.
12